Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

[1]  Jeffrey A Jones,et al.  Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Gonen,et al.  Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors , 2009, Clinical Cancer Research.

[3]  G. Schwartz,et al.  Development of cell-cycle inhibitors for cancer therapy , 2009, Current oncology.

[4]  Manuel Hidalgo,et al.  Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125 , 2008 .

[5]  R. Plummer,et al.  A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors , 2008 .

[6]  Jennifer L Moseley,et al.  A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies , 2008 .

[7]  C. Sander,et al.  Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. , 2007, Cancer research.

[8]  K. Wilner,et al.  A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991 , 2007 .

[9]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[11]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[12]  J. Wanders,et al.  Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[14]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Wilding,et al.  Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol , 2002, Cancer Chemotherapy and Pharmacology.

[16]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[17]  S. Steinberg,et al.  RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. , 1994, Oncogene.

[18]  J. Minna,et al.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.

[19]  W. Lee,et al.  Human retinoblastoma susceptibility gene: cloning, identification, and sequence , 1987, Science.

[20]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[21]  B. E. Eckbo,et al.  Appendix , 1826, Epilepsy Research.

[22]  S. Marinopoulos,et al.  Treatment of Growing Teratoma Syndrome , 2009 .

[23]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[24]  J. Yokota,et al.  Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. , 1988, Oncogene.